• Edwards Lifesciences Corp EW.N, EW is expected to show a fall in quarterly revenue when it reports results on July 24 for the period ending June 30 2025

• The Irvine California-based company is expected to report a 8.8% decrease in revenue to $1.489 billion from $1.63 billion a year ago, according to the mean estimate from 25 analysts, based on LSEG data.The company's guidance on April 23 2025, for the period ended June 30, was for revenue between $1.45 billion and $1.53 billion.

• ​LSEG's mean analyst estimate for Edwards Lifesciences Corp is for earnings of 62 cents per share. The company's EPS guidance on April 23 2025, for the period ended June 30, was between $0.59 and $0.65

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 15 "hold" and 1 "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Edwards Lifesciences Corp is $81.03, about 5.5% above its last closing price of $76.56

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated July 22 at 20:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)